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The concept of best treatment practice is a response to the growing diversity of thera-
peutic experience and to the frequently inadequacy of service reality and guidelines. Ideally, 
best practice guidelines are based on the available research evidence about effi cacy and 
effectiveness of therapeutic approaches. But limitations of outcome research must be 
taken into consideration as well as limitations of guideline applicability. Circumstantial 
factors are also relevant for treatment outcomes, and clinicians are expected to adapt 
evidence-based recommendations to such factors in their daily practice with individual 
patients. In addition, availability and access to recommended treatments are in the res-
ponsibility of service planners and providers, thereby facilitating the implementation of 
best practices. We understand best practice not as treatment provided in some centres 
of excellence, but as a system providing all those in need of treatment in the best pos-
sible way. Finally, major changes are expected for the future, redirecting the focus from a 
traditional evaluation of clinical usefulness for populations to an assessment of individually 
optimised interventions (personalised medicine: ‘treating the patient, not the disease”).
Abstract
Addiction treatment, best clinical practice, treatment outcome, service network, per-
sonalised medicine
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WHY BEST PRACTICE RULES?
The issue of normative guidelines and of 
best practice papers for the treatment and 
care of substance abuse disorders is a response 
to the increasing diversity of approaches and 
recommendations. Such recommendations are 
frequently not adequately backed up by scienti-
ﬁ c evidence on effi  cacy (from clinical trials) and 
/ or eff ectiveness (from observational studies), 
but often are fuelled by invested interests and 
ideological positions. 
More recently, research into deficits of 
treatment quality has shaken the credibility and 
eff ectiveness of services. Prominent studies 
came from USA and the EU. An analysis of 
a representative sample of addiction services 
in USA demonstrated a low professional 
status and a lack of competence due to high 
staff  turnover (McLellan, Carise and Kleber, 
2004). The European Commission funded a 
study into the management of high-risk opioid 
addicts which documented a major need for 
improvements in all treatment centres, in 
spite of great diff erences between centres 
(Haasen, Stallwitz, Lachmann et al., 2004). Also, 
treatment guidelines are not always reliable: an 
analysis of national guidelines for opioid subs-
titution treatments found major discrepancies 
and dissent in objectives and regulations and a 
deﬁ cit in evidence base (Uchtenhagen, Ladjevic 
and Rehm, 2005). 
Thereby, the need for a consensus on best 
practice standards and for their implementa-
tion became an urgent topic at national and 
international level.
UNDERSTANDING BEST 
PRACTICE CONCEPTS
The deﬁ nition of “best practice” provided 
by EMCDDA is “the best application of available 
evidence to current activities in the drugs ﬁ eld” 
(EMCDDA, 2012).
1. Underlying evidence should be relevant 
to the problems and issues aff ecting 
those involved (professionals, policy-
makers, drug users, their families); 
2. Methods should be transparent, reliable 
and transferable and all appropriate 
evidence should be considered in the 
classiﬁ cation process; 
3. Experience in implementation, adapta-
tion and training should be systematica-
lly collected and made available; 
4. Contextual factors should be studied by 
modeling diff erent prevalence levels so 
as to assess the impact of an interven-
tion on the population; and 
5. Evidence of eff ectiveness and feasibility 
of implementation should both be 
considered for the broader decision-
making process.
The “best practice portal” of EMCDDA 
provides continuously updated information 
on the available evidence on drug-related 
prevention, treatment and harm reduction 
interventions, focusing on a categorisation of 
evidence, as beneﬁ cial - likely to be beneﬁ cial 
– trade-off  between beneﬁ ts and harms – 
unknown eff ectiveness – evidence of ineff ec-
tiveness (EMCDDA, 2012).
Other deﬁ nitions are based on a similar 
understanding of best practice. For instance, 
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Health Canada has performed a review of 
reviews in order to determine best practice. 
It concluded with 23 best practice guidelines 
concerning speciﬁ c therapeutic approaches, 
target populations and service characteristics 
(Health Canada, 1999). 
Best practice is also conceptualized as the 
basis of intervention quality. Quality standards 
are deﬁ ned as “generally accepted principles or 
sets of rules for the best/most appropriate way 
to implement an intervention. Quality standards 
frequently refer to structural (formal) aspects 
of quality assurance, such as environment and 
staff  composition. However they may also refer 
to process aspects, such as adequacy of content, 
process of the intervention or evaluation proces-
ses” (EMCDDA, 2012).
The US Institute of Medicine has deﬁ ned 
quality as “the degree to which health services 
for individuals and populations increase the 
likelihood of desired health outcomes and are 
consistent with current professional knowled-
ge” (Lohr, 1990). The focus of this deﬁ nition 
on outcomes is consistent with the prevailing 
concept of evidence-based best practice.
Ideally, intervention guidelines are also 
based on scientiﬁ c evidence. The Institute 
of Medicine describes clinical guidelines as 
“statements that include recommendations 
intended to optimize patient care. They are 
informed by a systematic review of evidence 
and an assessment of the beneﬁ ts and harms 
of alternative care options” (Institute of Me-
dicine, 2011). One prominent example are 
the evidence-based NIDA Principles of drug 
addiction treatment (NIDA, 2009).
INTERNATIONAL ATTEMPTS AT 
STANDARD SETTING IN BEST 
PRACTICE
An early international instrument to mea-
sure a given treatment system against a set 
of standards were the WHO Schedules for 
the assessment of standards of care in subs-
tance abuse treatment (WHO, 1992). A ﬁ rst 
attempt at documenting the state of ethical 
standards, needs orientation, professional 
standards and evaluation standards in Euro-
pe was mandated by the WHO European 
Offi  ce in Copenhagen (Adequacy in Drug 
Abuse Treatment ADAT; Uchtenhagen & 
Guggenbühl, 2000). More recently, WHO and 
UNODC jointly published a discussion paper 
on 9 principles of drug dependence treatment 
(UNODC and WHO, 2008), which will be 
further elaborated in the ongoing project 
Substance Abuse Instrument for Mapping 
Services SAIMS (WHO, 2012). Best practice 
papers for speciﬁ c issues (Community based 
treatments, drug treatment and rehabilitation 
in closed settings, role of drug treatment and 
rehabilitation in HIV/AIDS prevention and 
care, sustainable livelihoods for reintegration 
and rehabilitation) have been produced as a 
component of the worldwide training project 
TREATNET of UNODC (Tomàs-Rossello 
et al., 2010). Comprehensive guidelines 
for psychosocially assisted pharmacological 
treatments of opioid dependence were pu-
blished by WHO (WHO, 2009).
THE ROLE OF SCIENTIFIC 
EVIDENCE 
The concept of best practice has two com-
ponents: one is the scientiﬁ c evidence on which 
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recommendations are based, the other is the 
“best application” of the evidence.
Scientiﬁ c evidence has diff erent types, and 
these types have been classiﬁ ed as ‘grades of 
evidence’. An internationally recognised system 
was developed by the GRADE working group 
(Guyatt, Oxman, Kunz et al., 2008; GRADE 
Working Group, 2012). Another attempt 
developed standards for a consensus building 
process, where experimental research is not 
feasible: the AGREE concept (AGREE, 2009).
The gold standard of generating scientiﬁ c 
evidence in medical science and beyond are 
randomised controlled studies (RCT). Mul-
tiple RCTs with converging evidence are the 
basis for the highest grade of evidence. Two 
internationally established research groups 
use RCT based evidence for their reviews: the 
Cochrane Collaboration (Cochrane, 2012) in 
the health ﬁ eld and the Campbell Collabora-
tion for social interventions (Campbell, 2012).
LIMITATIONS OF RESEARCH 
EVIDENCE 
However, not all topics are open to experi-
mentation with randomisation methods. For 
instance, the role of patient-therapist relation-
ship, the ‘doctor as medicine’, as a determining 
factor for treatment outcomes is well known 
but hardly to be identiﬁ ed by RCT. The gold 
standard is not applicable to all aspects of the-
rapeutic processes. Also, qualitative research 
can generate relevant information where the 
ﬁ ndings of quantitative research are open to 
simplistic interpretation, e.g. information on 
the treatment expectations of patients (Neale, 
Nettleton and Pickering, 2011). 
An increasingly researched factor comple-
menting evidence-based guidelines is patient 
satisfaction. Patient satisfaction is an important 
element in eff ectiveness research which should 
complement effi  cacy research (randomisation, 
use of control conditions) in order to over-
come the gap between RTC based evidence 
and its use in clinical practice (Carroll and 
Rounsaville, 2003). 
Methodological limitations are to be men-
tioned. Randomised controlled studies usually 
focus on homogeneous populations, and they 
do not include persons who refuse to partici-
pate in an RCT, which limits the generalisability 
of ﬁ ndings. Also, RCT usually to not take into 
account concomitant medications and other 
interventions which play a relevant role in 
practice (Geleris and Boudoulas, 2011).
Another critical issue is the measurement of 
treatment outcome. Research studies focusing 
on abstinence rates are prone to produce 
diff erent evidence of effi  cacy than studies 
measuring diff erentiated changes in addictive 
behaviours and consumption, and even more 
than studies looking at additional health and 
social outcomes (Uchtenhagen, 2012).
Finally, it must be considered how guidelines 
are set up. Work from developing countries 
show that several factors increase the impact 
of practice guidelines: involvement of the 
end-users in guidelines development, launch 
and introduction of the guidelines, multiple 
training modalities, feedback to prescribers 
on their prescription practices (Ross-Degnan 
et al., 1997).
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LIMITATIONS OF GUIDELINE 
APPLICABILITY
Evidence-based guidelines have an enor-
mous value. Some limitations of applicability 
must be remembered all the same. They are 
mainly a consequence of how guidelines are 
set up. 
 - External validity (generalisability) of ﬁ ndings 
from RCTs is often inadequate and makes 
applicability diffi  cult (Rothwell, 2005).
 - It is possible that the expected outcomes 
as predicted by effi  cacy studies will not be 
attained when implemented under ﬁ eld 
conditions and in diff erent socio-cultural 
settings (Lohr, Eleazer and Mauskopf, 1998).
 - A variable number of individual cases does 
not allow to apply the recommended 
treatment, but the guidelines provide no 
guidance how to proceed with exceptions.
 - The half-life of guidelines is getting shorter 
with the increase of treatment research; 
non-updated guidelines have a risk for 
misinformation and outdated recommen-
dations.
BEST PRACTICE IS MORE THAN 
A SET OF EVIDENCE-BASED 
RULES
If best practice is based exclusively on the 
best available evidence, there is a risk to disre-
gard other factors which can be considered to 
be relevant for eff ective therapeutic practice. 
And as far as treatment guidelines are based on 
the best available evidence, we are faced with 
problems of guideline applicability. Also, best 
evidence on effi  cacy and eff ectiveness are not 
suffi  cient for strategic decisions on treatment 
availability at the system level. Finally we must 
consider a few basic questions on the role 
of addiction treatment. In this perspective, 
best practice has to build on knowledge of 
and respect for research evidence, but also 
on knowledge of and respect for all circums-
tantial factors which have an impact on good 
treatment outcomes. 
The following are examples from everyday 
practice. Some are quite banal, others more 
speciﬁ c. 
 - Availability of a recommended treatment, 
in a given region with adequate quality and 
aff ordable costs.
 - Therapist familiarity with the relevant 
treatment options.
 - Therapist willingness to refer a patient to 
a recommended treatment in case he or 
she has no training or infrastructure for 
this treatment.
 - Patient is ready to accept and comply with 
a recommended treatment.
The absence of any one of these factors 
creates problems for implementing the recom-
mended treatment or for a satisfactory outco-
me. Best practice means ﬁ nding an acceptable 
therapeutic answer under the given conditions 
which may not be, and often enough are not, 
ideal (Summerskill, 2005).
For the therapist, this is the great challenge 
in daily practice. “The responsibility remains 
with the clinician to combine this evidence 
with clinical expertise and patient values in 
managing individual patients and achieving 
optimal outcomes” (Scalzitti, 2001). To provide 
a treatment network or system which allows 
for implementing best practice is another 
responsibility.
Ambros Uchtenhagen
398 Revista Españolade
Drogodependencias 37 (4) 2012
STRATEGIC FACTORS AT THE 
SYSTEM LEVEL
Service providers and planners are responsi-
ble for developing the treatment network into 
a system where the implementation of best 
treatment practice is facilitated. This includes 
strategic decisions which go beyond the usual 
guideline recommendations. 
 - Guidelines usually recommend how a given 
treatment should be performed, but not if 
a given treatment should be made available.
 - Best practice guidelines rarely provide 
minimum recommendations in case best 
practice is not available or aff ordable; an 
exception are the WHO Guidelines on 
psychosocially assisted pharmacological 
treatments of opioid dependence (WHO, 
2009).
 - Guidelines recommend how a treatment in-
dication should be made, but not who -and 
on the basis of which criteria- is entitled to 
determine the indication; in some models 
of stepped care in addiction treatment the 
indication is no longer in the competence 
of services but of a central assessment and 
indication group (Schippers, Schramade and 
Walburg, 2002).
 - Guidelines provide standards for treatment 
quality, but not for treatment coverage 
(scope of services in response to estima-
ted treatment needs in the population); an 
analysis of guidelines and other documents 
at international level found no standards or 
benchmarks for coverage (Uchtenhagen 
and Schaub, 2011).
Treatment systems have their own invested 
interests, and therapeutic recommendations 
navigate in a ﬁ eld of conﬂ icting interests. The 
most prominent examples are the controversy 
between drug-free approaches and mainte-
nance programmes (so far limited to opioid 
and nicotine replacement therapies), and the 
controversy between addiction treatment and 
harm reduction interventions. The paradigm 
of an integrated treatment and care system, 
where all approaches have their speciﬁ c place 
and function, is a promising answer to this 
struggle (Stevens, Hallam and Trace, 2006).
Usually, treatment systems and services are 
not built up from scratch. The problem is not 
how to set up the perfect system, but how to 
improve the existing system. This is not only 
a matter of continued education and training 
of staff . Health policy is about updating and 
improving the system in response to changing 
population needs, changing patient characteris-
tics and changing research evidence. Research 
which is speciﬁ cally focusing on service im-
provement has a major role to play. Examples 
are the US National Treatment Improvement 
Evaluation Survey NTIES and the WHO ins-
trument SAIMS. NTIES demonstrated how the 
assessment of patient needs at entry inﬂ uence 
the therapeutic outcome (Gerstein et al., 
1997). SAIMS is an instrument for assessing 
and improving national systems for drug pre-
vention and treatment (WHO, 2012).
Strategic decisions therefore are about prio-
rities: which therapeutic approaches have to 
be made available or developed, what is an 
acceptable balance of coverage and quality 
of treatment, how can best use be made of 
the available human and ﬁ nancial resources 
in order to facilitate the best possible way of 
good practice implementation.
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AND THE FUTURE?
Major changes in medical concepts are 
under way. Molecular genetics generate data 
which allow to assess individual risk factors, 
health potentials, treatment responsiveness 
and interactions with the environment. The 
concept of personalised medicine is more than 
a vision and develops into the ‘P4 medicine’ 
(predictive, preventive, personalised and par-
ticipative medicine). New standardised tools 
will be required for clinical decision support 
(Ginsburg and Willard, 2009). The implica-
tions for optimising addiction treatment are a 
challenge for the future. 
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